Case Study

Phase III Rare Disease Rescue

Patient Recruitment

A small biotech with limited internal capacity outsourced a phase III clinical program in patients with Necrotizing Soft Tissue Infections, a rare, life threatening infection for which no therapy currently exists, to a CRO. The study was to be conducted with 60 US sites with the objective of enrolling 290 patients.

After nearly 16 months, patient enrollment was still a major challenge and the CRO was not proactive in addressing the issues and providing solutions. Adding to the difficulties, the study was over budget and CRO staff turnover on the project was extremely high. The CRO-Sponsor relationship had deteriorated significantly. The Sponsor wanted control back.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: